Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. May 28, 2009; 15(20): 2506-2511
Published online May 28, 2009. doi: 10.3748/wjg.15.2506
Published online May 28, 2009. doi: 10.3748/wjg.15.2506
Etiology | HCC n (%) | Age (yr) | Prevalence of DM2 (%) |
HBV | 20 (4.3) | 63.3 ± 10.3a | 3 (15.0) |
HCV | 177 (38.1) | 71.5 ± 7.3a | 47 (26.5)bc |
Alcohol | 141 (30.4) | 66.7 ± 8.5a | 52 (36.9)bd |
HBV + HCV | 8 (1.7) | 60.8 ± 12.8a | 2 (25.0) |
HBV + alcohol | 9 (1.9) | 62.9 ± 9.3a | 2 (22.2) |
HCV + alcohol | 81 (17.4) | 67.7 ± 9.3a | 27 (33.3) |
HBV + HCV + alcohol | 2 (0.4) | 68.4 ± 10.3 | 0 |
Cryptogenic | 27 (5.8) | 68.6 ± 9.3 | 19 (70.3)cd |
- Citation: Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G, Miranda C. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009; 15(20): 2506-2511
- URL: https://www.wjgnet.com/1007-9327/full/v15/i20/2506.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.2506